Considerations for the sensible use of rodent models of inflammatory disease in predicting efficacy of new biological therapeutics in the clinic

Advanced Drug Delivery Reviews

Volumn 59, Issue 11, 2007, Pages 1084-1092

  Arnett, Heather A ^a   Viney, Joanne L ^a  

^a AMGEN INC   (United States)

Author keywords

Animal models; Asthma; Biologics; Inflammation; Multiple sclerosis; Rheumatoid arthritis

Indexed keywords

ANIMAL MODELS; ASTHMA; BIOLOGICS; INFLAMMATION; RHEUMATOID ARTHRITIS;

COMPUTER SIMULATION; DISEASES; IMMUNIZATION; RATS;

DRUG DELIVERY;

ABATACEPT; ADALIMUMAB; AMG 317; ANTIASTHMATIC AGENT; ANTIRHEUMATIC AGENT; ATLIZUMAB; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BETA INTERFERON; BETA1A INTERFERON; CORTICOSTEROID; ECULIZUMAB; EFALIZUMAB; ETANERCEPT; GLATIRAMER; GLUCOCORTICOID; INFLIXIMAB; INTERFERON BETA SERINE; INTERLEUKIN 13; INTERLEUKIN 13 ANTIBODY; INTERLEUKIN 4; NATALIZUMAB; OMALIZUMAB; PITRAKINRA; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TNX 650; TRU 015; UNCLASSIFIED DRUG;

ASTHMA; BIOLOGICAL MODEL; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SYNTHESIS; GENE OVEREXPRESSION; HUMAN; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; ASTHMA; BIOLOGICAL PRODUCTS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; HUMANS; MICE; MULTIPLE SCLEROSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 35349021440     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2007.06.013     Document Type: Review

References (104)

1. Sospedra M., and Martin R. Immunology of multiple sclerosis. Annu. Rev. Immunol. 23 (2005) 683-747
2. Koritschoner R.S., and Schweinburg F. Induktion von Paralyse und Rückenmarksentzündung durch Immunisierung von Kaninchen mit menschlichem Rückenmarksgewebe. Z. Immunitätsforsch. Exp. Ther. 42 (1925) 217-283
3. Hemmer B., et al. Immunopathogenesis and immunotherapy of multiple sclerosis. Nat. Clin. Pract. Neurol. 2 4 (2006) 201-211
4. Gold R., Linington C., and Lassmann H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 129 Pt 8 (2006) 1953-1971
5. Huseby E.S., et al. A pathogenic role for myelin-specific CD8(+) T cells in a model for multiple sclerosis. J. Exp. Med. 194 5 (2001) 669-676
6. Babbe H., et al. Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J. Exp. Med. 192 3 (2000) 393-404
7. Hauser S.L., et al. Immunohistochemical analysis of the cellular infiltrate in multiple sclerosis lesions. Ann. Neurol. 19 6 (1986) 578-587
8. Traugott U., Reinherz E.L., and Raine C.S. Multiple sclerosis: distribution of T cell subsets within active chronic lesions. Science 219 4582 (1983) 308-310
9. Kim B.S., et al. Innate immune response induced by Theiler's murine encephalomyelitis virus infection. Immunol. Res. 31 1 (2005) 1-12
10. Oleszak E.L., et al. Theiler's virus infection: a model for multiple sclerosis. Clin. Microbiol. Rev. 17 1 (2004) 174-207
11. Lucchinetti C., et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 47 6 (2000) 707-717
12. Matsushima G.K., and Morell P. The neurotoxicant, cuprizone, as a model to study demyelination and remyelination in the central nervous system. Brain Pathol. 11 1 (2001) 107-116
13. Woodruff R.H., and Franklin R.J. Demyelination and remyelination of the caudal cerebellar peduncle of adult rats following stereotaxic injections of lysolecithin, ethidium bromide, and complement/anti-galactocerebroside: a comparative study. Glia 25 3 (1999) 216-228
14. Arnett H.A., et al. TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination. Nat. Neurosci. 4 11 (2001) 1116-1122
15. Theien B.E., et al. Discordant effects of anti-VLA-4 treatment before and after onset of relapsing experimental autoimmune encephalomyelitis. J. Clin. Invest. 107 8 (2001) 995-1006
16. Brocke S., et al. Antibodies to CD44 and integrin alpha4, but not L-selectin,prevent central nervous system inflammation and experimental encephalomyelitis by blocking secondary leukocyte recruitment. Proc. Natl. Acad. Sci. U. S. A. 96 12 (1999) 6896-6901
17. Kent S.J., et al. A monoclonal antibody to alpha 4 integrin suppresses and reverses active experimental allergic encephalomyelitis. J. Neuroimmunol. 58 1 (1995) 1-10
18. Yednock T.A., et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 356 6364 (1992) 63-66
19. Polman C.H., et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 354 9 (2006) 899-910
20. Kleinschmidt-DeMasters B.K., and Tyler K.L. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N. Engl. J. Med. 353 4 (2005) 369-374
21. Langer-Gould A., et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N. Engl. J. Med. 353 4 (2005) 375-381
22. Van Assche G., et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N. Engl. J. Med. 353 4 (2005) 362-368
23. Koralnik I.J. New insights into progressive multifocal leukoencephalopathy. Curr. Opin. Neurol. 17 3 (2004) 365-370
24. Cross A.H., and Stark J.L. Humoral immunity in multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis. Immunol. Res. 32 1-3 (2005) 85-97
25. Amit Bar-Or P.C., Arnold D., Markowitz C., Shafer S., Kasper L., Waubant E., Gazda S., Fox R., Sarkar N., Panzara M., and Smith C. A phase I, open-label, multicenter study to evaluate the safety and activity of rituximab in adults with Relapsing-Remitting Multiple Sclerosis (RRMS). 59th Annual Meeting of the American Academy of Neurology (2007) Abstract #S02.001
26. Stephen Hauser E.W., Arnold Douglas., Vollmer T., Antel a., Fox R., Bar-Or A., Sarkar N., Langer-Gould A., Panzara M., and Smith C. A phase II randomized, placebo-controlled, multicenter trial of rituximab in adults with Relapsing Remitting Multiple Sclerosis (RRMS). 59th Annual Meeting of the American Academy of Neurology (2007) Abstract #S12.003
27. Drescher K.M., et al. TGF-beta 2 reduces demyelination, virus antigen expression, and macrophage recruitment in a viral model of multiple sclerosis. J. Immunol. 164 6 (2000) 3207-3213
28. Kuruvilla A.P., et al. Protective effect of transforming growth factor beta 1 on experimental autoimmune diseases in mice. Proc. Natl. Acad. Sci. U. S. A. 88 7 (1991) 2918-2921
29. Racke M.K., et al. Prevention and treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-beta 1. J. Immunol. 146 9 (1991) 3012-3017
30. Racke M.K., et al. Long-term treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-beta 2. J. Neuroimmunol. 46 1-2 (1993) 175-183
31. Calabresi P.A., et al. Phase 1 trial of transforming growth factor beta 2 in chronic progressive MS. Neurology 51 1 (1998) 289-292
32. Ruuls S.R., et al. The length of treatment determines whether IFN-beta prevents or aggravates experimental autoimmune encephalomyelitis in Lewis rats. J. Immunol. 157 12 (1996) 5721-5731
33. Njenga M.K., et al. Short-term treatment with interferon-alpha/beta promotes remyelination, whereas long-term treatment aggravates demyelination in a murine model of multiple sclerosis. J. Neurosci. Res. 59 5 (2000) 661-670
34. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology 43 4 (1993) 655-661
35. Paty D.W., and Li D.K. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 43 4 (1993) 662-667
36. Croxford J.L., et al. Local gene therapy with CTLA4-immunoglobulin fusion protein in experimental allergic encephalomyelitis. Eur. J. Immunol. 28 12 (1998) 3904-3916
37. Perrin P.J., et al. Role of B7:CD28/CTLA-4 in the induction of chronic relapsing experimental allergic encephalomyelitis. J. Immunol. 154 3 (1995) 1481-1490
38. Perrin P.J., et al. B7-mediated costimulation can either provoke or prevent clinical manifestations of experimental allergic encephalomyelitis. Immunol. Res. 14 3 (1995) 189-199
39. Arima T., et al. Inhibition by CTLA4Ig of experimental allergic encephalomyelitis. J. Immunol. 156 12 (1996) 4916-4924
40. Cross A.H., et al. Long-term inhibition of murine experimental autoimmune encephalomyelitis using CTLA-4-Fc supports a key role for CD28 costimulation. J. Clin. Invest. 95 6 (1995) 2783-2789
41. Khoury S.J., et al. CD28-B7 costimulatory blockade by CTLA4Ig prevents actively induced experimental autoimmune encephalomyelitis and inhibits Th1 but spares Th2 cytokines in the central nervous system. J. Immunol. 155 10 (1995) 4521-4524
42. Neville K.L., et al. CD28 costimulatory blockade exacerbates disease severity and accelerates epitope spreading in a virus-induced autoimmune disease. J. Virol. 74 18 (2000) 8349-8357
43. Bright J.J., Rodriguez M., and Sriram S. Differential influence of interleukin-12 in the pathogenesis of autoimmune and virus-induced central nervous system demyelination. J. Virol. 73 2 (1999) 1637-1639
44. Constantinescu C.S., et al. Antibodies against IL-12 prevent superantigen-induced and spontaneous relapses of experimental autoimmune encephalomyelitis. J. Immunol. 161 9 (1998) 5097-5104
45. Cua D.J., et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421 6924 (2003) 744-748
46. Inoue A., et al. Suppressive effect on Theiler's murine encephalomyelitis virus-induced demyelinating disease by the administration of anti-IL-12 antibody. J. Immunol. 161 10 (1998) 5586-5593
47. Epstein M.M. Do mouse models of allergic asthma mimic clinical disease?. Int. Arch. Allergy Immunol. 133 1 (2004) 84-100
48. Kumar R.K., and Foster P.S. Modeling allergic asthma in mice: pitfalls and opportunities. Am. J. Respir. Cell Mol. Biol. 27 3 (2002) 267-272
49. Ramos-Barbon D., Ludwig M.S., and Martin J.G. Airway remodeling: lessons from animal models. Clin. Rev. Allergy Immunol. 27 1 (2004) 3-21
50. Temann U.A., et al. Expression of interleukin 9 in the lungs of transgenic mice causes airway inflammation, mast cell hyperplasia, and bronchial hyperresponsiveness. J. Exp. Med. 188 7 (1998) 1307-1320
51. Zhu Z., et al. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J. Clin. Invest. 103 6 (1999) 779-788
52. Elias J.A., et al. Airway remodeling in asthma. J. Clin. Invest. 104 8 (1999) 1001-1006
53. Tamachi T., et al. IL-25 enhances allergic airway inflammation by amplifying a TH2 cell-dependent pathway in mice. J. Allergy Clin. Immunol. 118 3 (2006) 606-614
54. Strunk R.C., and Bloomberg G.R. Omalizumab for asthma. N. Engl. J. Med. 354 25 (2006) 2689-2695
55. D'Amato G. Role of anti-IgE monoclonal antibody (omalizumab) in the treatment of bronchial asthma and allergic respiratory diseases. Eur. J. Pharmacol. 533 1-3 (2006) 302-307
56. Mehlhop P.D., et al. Allergen-induced bronchial hyperreactivity and eosinophilic inflammation occur in the absence of IgE in a mouse model of asthma. Proc. Natl. Acad. Sci. U. S. A. 94 4 (1997) 1344-1349
57. Hamelmann E., et al. Role of IgE in the development of allergic airway inflammation and airway hyperresponsiveness-a murine model. Allergy 54 4 (1999) 297-305
58. Coyle A.J., et al. Central role of immunoglobulin (Ig) E in the induction of lung eosinophil infiltration and T helper 2 cell cytokine production: inhibition by a non-anaphylactogenic anti-IgE antibody. J. Exp. Med. 183 4 (1996) 1303-1310
59. Haile S., et al. Suppression of immediate and late responses to antigen by a non-anaphylactogenic anti-IgE antibody in a murine model of asthma. Eur. Respir. J. 13 5 (1999) 961-969
60. Heusser C.H., et al. Demonstration of the therapeutic potential of non-anaphylactogenic anti-IgE antibodies in murine models of skin reaction, lung function and inflammation. Int. Arch. Allergy Immunol. 113 1-3 (1997) 231-235
61. Tumas D.B., et al. Anti-IgE efficacy in murine asthma models is dependent on the method of allergen sensitization. J. Allergy Clin. Immunol. 107 6 (2001) 1025-1033
62. Choi I.W., et al. TNF-alpha induces the late-phase airway hyperresponsiveness and airway inflammation through cytosolic phospholipase A(2) activation. J. Allergy Clin. Immunol. 116 3 (2005) 537-543
63. Kim J., et al. Anti-tumor necrosis factor-alpha antibody treatment reduces pulmonary inflammation and methacholine hyper-responsiveness in a murine asthma model induced by house dust. Clin. Exp. Allergy 36 1 (2006) 122-132
64. Erin E.M., et al. The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma. Am. J. Respir. Crit. Care Med. 174 7 (2006) 753-762
65. Berry M.A., et al. Evidence of a role of tumor necrosis factor alpha in refractory asthma. N. Engl. J. Med. 354 7 (2006) 697-708
66. Howarth P.H., et al. Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax 60 12 (2005) 1012-1018
67. Tang M.L., and Fiscus L.C. Important roles for L-selectin and ICAM-1 in the development of allergic airway inflammation in asthma. Pulm. Pharmacol. Ther. 14 3 (2001) 203-210
68. Bloemen P.G., et al. LFA-1, and not Mac-1, is crucial for the development of hyperreactivity in a murine model of nonallergic asthma. Am. J. Respir. Crit. Care Med. 153 2 (1996) 521-529
69. Iwamoto I., and Nakao A. Induction of Th2 cell tolerance to a soluble antigen by blockade of the LFA-1-dependent pathway prevents allergic inflammation. Immunol. Res. 14 4 (1995) 263-270
70. Keramidaris E., et al. L-selectin and intercellular adhesion molecule 1 mediate lymphocyte migration to the inflamed airway/lung during an allergic inflammatory response in an animal model of asthma. J. Allergy Clin. Immunol. 107 4 (2001) 734-738
71. Gauvreau G.M., et al. The effects of an anti-CD11a mAb, efalizumab, on allergen-induced airway responses and airway inflammation in subjects with atopic asthma. J. Allergy Clin. Immunol. 112 2 (2003) 331-338
72. Brusselle G., et al. Allergen-induced airway inflammation and bronchial responsiveness in wild-type and interleukin-4-deficient mice. Am. J. Respir. Cell Mol. Biol. 12 3 (1995) 254-259
73. Coyle A.J., et al. Interleukin-4 is required for the induction of lung Th2 mucosal immunity. Am. J. Respir. Cell Mol. Biol. 13 1 (1995) 54-59
74. Gavett S.H., et al. Interleukin-4 receptor blockade prevents airway responses induced by antigen challenge in mice. Am. J. Physiol. 272 2 Pt 1 (1997) L253-L261
75. Grunig G., et al. Requirement for IL-13 independently of IL-4 in experimental asthma. Science 282 5397 (1998) 2261-2263
76. Wills-Karp M., et al. Interleukin-13: central mediator of allergic asthma. Science 282 5397 (1998) 2258-2261
77. Cheng G., et al. Anti-interleukin-9 antibody treatment inhibits airway inflammation and hyperreactivity in mouse asthma model. Am. J. Respir. Crit. Care Med. 166 3 (2002) 409-416
78. Stuart J.M., Townes A.S., and Kang A.H. Collagen autoimmune arthritis. Annu. Rev. Immunol. 2 (1984) 199-218
79. Trentham D.E., Townes A.S., and Kang A.H. Autoimmunity to type II collagen an experimental model of arthritis. J. Exp. Med. 146 3 (1977) 857-868
80. Nandakumar K.S., and Holmdahl R. Antibody-induced arthritis: disease mechanisms and genes involved at the effector phase of arthritis. Arthritis Res. Ther. 8 6 (2007) 223
81. Waksman B.H. Immune regulation in adjuvant disease and other arthritis models: relevance to pathogenesis of chronic arthritis. Scand. J. Immunol. 56 1 (2002) 12-34
82. Sakaguchi S., and Sakaguchi N. Animal models of arthritis caused by systemic alteration of the immune system. Curr. Opin. Immunol. 17 6 (2005) 589-594
83. Thorbecke G.J., et al. Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen type II arthritis in mice. Proc. Natl. Acad. Sci. U. S. A. 89 16 (1992) 7375-7379
84. Williams R.O., Feldmann M., and Maini R.N. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc. Natl. Acad. Sci. U. S. A. 89 20 (1992) 9784-9788
85. Piguet P.F., et al. Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. Immunology 77 4 (1992) 510-514
86. Wooley P.H., et al. Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice. J. Immunol. 151 11 (1993) 6602-6607
87. Scott D.L., and Kingsley G.H. Tumor necrosis factor inhibitors for rheumatoid arthritis. N. Engl. J. Med. 355 7 (2006) 704-712
88. van den Berg W.B. Arguments for interleukin 1 as a target in chronic arthritis. Ann. Rheum. Dis. 59 Suppl 1 (2000) i81-i84
89. Cohen S., et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 46 3 (2002) 614-624
90. Kliwinski C., et al. Prophylactic administration of abatacept prevents disease and bone destruction in a rat model of collagen-induced arthritis. J. Autoimmun. 25 3 (2005) 165-171
91. Knoerzer D.B., et al. Collagen-induced arthritis in the BB rat. Prevention of disease by treatment with CTLA-4-Ig. J. Clin. Invest. 96 2 (1995) 987-993
92. Webb L.M., Walmsley M.J., and Feldmann M. Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway: requirement for both B7-1 and B7-2. Eur. J. Immunol. 26 10 (1996) 2320-2328
93. Kremer J.M., et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 52 8 (2005) 2263-2271
94. Dunussi-Joannopoulos K., et al. B-cell depletion inhibits arthritis in a collagen-induced arthritis (CIA) model, but does not adversely affect humoral responses in a respiratory syncytial virus (RSV) vaccination model. Blood 106 7 (2005) 2235-2243
95. Edwards J.C., et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 350 25 (2004) 2572-2581
96. Smolen J.S., et al. Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann. Rheum. Dis. 66 2 (2007) 143-150
97. Gross J.A., et al. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. Impaired B cell maturation in mice lacking BLyS. Immunity 15 2 (2001) 289-302
98. Wang H., et al. TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice. Nat. Immunol. 2 7 (2001) 632-637
99. Alonzi T., et al. Interleukin 6 is required for the development of collagen-induced arthritis. J. Exp. Med. 187 4 (1998) 461-468
100. Maini R.N., et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 54 9 (2006) 2817-2829
101. Nishimoto N., et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 50 6 (2004) 1761-1769
102. Wang Y., et al. Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease. Proc. Natl. Acad. Sci. U. S. A. 92 19 (1995) 8955-8959
103. Freim Wahl S.G., Folvik M.R., and Torp S.H. Progressive multifocal leukoencephalopathy in a lymphoma patient with complete remission after treatment with cytostatics and rituximab: case report and review of the literature. Clin. Neuropathol. 26 2 (2007) 68-73
104. FDA. http://www.fda.gov/bbs/topics/NEWS/2006/NEW01532.html. FDA Warns of Safety Concern Regarding Rituxan in New Patient Population [cited 2006 December 18].